Differential role of protein tyrosine phosphorylation/dephosphorylation in affinity regulation of beta 1 and beta 3 integrin in human fibroblasts.
We investigated the effects of protein tyrosine phosphatase inhibitors, pervanadate and phenylarsine oxide (PAO), on the beta 1 and beta 3 integrin-mediated cell-substrate interaction using normal diploid human fibroblast. Pervanadate treatment of the cells in suspension state resulted in highly elevated levels of cellular protein tyrosine phosphorylation accompanied by loss of beta 1 integrin-mediated adhesion to substrata (i.e., collagen and laminin). In contrast, beta 3 integrin-mediated adhesion to substrata (i.e., fibronectin and vitronectin) of these cells was less affected. Moreover, pervanadate could reverse beta 1 integrin-dependent adhesion, and cells already adhered on collagen or laminin, but not on fibronectin or vitronectin, came off within 30 min upon pervanadate treatment. These effects are likely to be directly mediated by increased cellular protein tyrosine phosphorylation, because another chemical compound, PAO, which also inhibits protein tyrosine phosphatase through a quite different mechanism, also exhibited the specific deterioration of beta 1 integrin-mediated cell-substrate interaction. Upon treatment with these protein tyrosine phosphatase inhibitors, the well developed actin stress fibers were disrupted resulting in the rounding up of cells on fibronectin and vitronectin substrate though they were still attached to the beta 3 integrin-dependent substrates. Using immunoprecipitation and anti-phosphotyrosine immunoblotting, beta 1 integrin itself was shown not to be tyrosine phosphorylated. These results indicate that affinity regulation of beta 1 and beta 3 integrin is differentially controlled and that the specific regulation of beta 1 integrin is due to certain cellular component(s) whose activity is modulated by tyrosine phosphorylation/dephosphorylation.
Takagi
J
J
Department of Biological Sciences, Faculty of Bioscience and Biotechnology, Tokyo Institute of Technology, Yokohama, Japan.
Saito
Y
Y
D000911:Antibodies, Monoclonal; D015703:Antigens, CD / Q000276:immunology / Q000378:metabolism*; D001152:Arsenicals / Q000494:pharmacology; D002448:Cell Adhesion / Q000502:physiology; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005347:Fibroblasts / Q000378:metabolism* / Q000648:ultrastructure; D006801:Humans; D019012:Integrin beta1 / Q000276:immunology / Q000378:metabolism*; D039661:Integrin beta3; D016023:Integrins / Q000276:immunology / Q000378:metabolism*; D010766:Phosphorylation; D010980:Platelet Membrane Glycoproteins / Q000276:immunology / Q000378:metabolism*; D014443:Tyrosine / Q000378:metabolism*; D014638:Vanadates / Q000494:pharmacology
D000911:Antibodies, Monoclonal; D015703:Antigens, CD; D001152:Arsenicals; D004791:Enzyme Inhibitors; D019012:Integrin beta1; D039661:Integrin beta3; D016023:Integrins; D010980:Platelet Membrane Glycoproteins; C076715:pervanadate; C029341:oxophenylarsine; D014638:Vanadates; D014443:Tyrosine